<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1561">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542031</url>
  </required_header>
  <id_info>
    <org_study_id>2020COV113</org_study_id>
    <nct_id>NCT04542031</nct_id>
  </id_info>
  <brief_title>COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL</brief_title>
  <official_title>COVID-19 Prevalence in a Single Large UK Rheumatology Centre and the Impact on Quality of Life From Stringent Social Distancing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Royal Wolverhampton Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Royal Wolverhampton Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 pandemic represents a threat to rheumatology patients. National advice for
      patients to 'shield' is based on risk stratification of therapies and other risk factors.
      While the epidemiology of COVID-19 in the rheumatological population is largely unknown large
      case registries are beginning to show potential drug treatment interactions. Strict
      self-isolation (shielding) has been recommended for those deemed 'high risk' although its
      impact on the likelihood of COVID-19 infection and health related quality of life (HRQoL) is
      unclear.

      The study aims to explore how this unprecedented situation has impacted the Trust patients
      primarily evaluating prevalence of the infection, effect of stringent social distancing
      (shielding) and Quality of Life (QOL). This will be done via a voluntary questionnaire, sent
      via text messaging at 6 and 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of COVID 19</measure>
    <time_frame>1 year</time_frame>
    <description>percentage of cases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality rates from COVID 19</measure>
    <time_frame>1 year</time_frame>
    <description>number of deaths per 1000 individuals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health related quality of life - Short Form 12</measure>
    <time_frame>1 year</time_frame>
    <description>mental and physical component scores through patient reported outcomes. Normative score set at 50 with minimum score being 0 and maximum score being 100. Scores &gt;50 indicate better mental or physical health than the mean. Scores &lt;50 indicate worse mental or physical health than the mean</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7911</enrollment>
  <condition>Covid19</condition>
  <condition>Rheumatic Diseases</condition>
  <arm_group>
    <arm_group_label>Survey</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Survey to be distributed at 6 and 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questionnaire to be completed at 6 and 12 months</description>
    <arm_group_label>Survey</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All rheumatology patients under active follow up at the Royal Wolverhampton Trust with
             a validated mobile telephone number

        Exclusion Criteria:

          -  Patients without a validated mobile phone number linked to their hospital record
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Bateman</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Wolverhampton NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Bateman</last_name>
    <phone>01902307999</phone>
    <email>jamesbateman@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natasha Cleaton</last_name>
    <email>natasha.cleaton@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Royal Wolverhampton NHS Trust</name>
      <address>
        <city>Wolverhampton</city>
        <state>West Midlands</state>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>James Bateman</last_name>
      <email>jamesbateman@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

